Congress passes Ebola 'voucher' bill
This article was originally published in Scrip
Executive Summary
The House and the Senate last week passed legislation aimed at adding Ebola to the list of qualified neglected tropical diseases for which biopharmaceutical makers can gain an FDA priority review voucher (PRV) if the firms develop drugs or vaccines to treat the deadly virus, which has infected more than 17,500 people and killed nearly 6,200 in the current outbreak.